CASSAVA SCIENCES INC

Company Overview

Cassava Sciences (SAVA) is a clinical-stage biotechnology company focused on central nervous system disorders, principally Alzheimer’s disease and TSC‑related epilepsy. Its lead development asset is simufilam (an oral small molecule) and an early-stage blood biomarker SavaDx; the company has no approved products and historically ran large multinational Phase 1–3 programs. Recent operational shifts include the wind‑down of two Phase 3 Alzheimer’s trials after RETHINK‑ALZ failed its co‑primary endpoints (Nov 2024), a pivot toward a Yale‑licensed TSC epilepsy program (Feb 2025), a sharp reduction in R&D spend, a $40M SEC settlement in 2024, and a lean outsourced operating model dependent on CROs/CDMOs. Cash was about $128.6M at year‑end 2024 and $112.4M at June 30, 2025, and management warns financing needs and clinical/regulatory uncertainty are principal near‑term risks.

Executive Compensation Practices

As a small biotechnology firm in the Healthcare / Biotechnology (Pharmaceutical Products) space, executive pay at Cassava is equity‑heavy and tightly linked to clinical and financing milestones rather than sustained commercial revenues. Filings show material increases in stock‑based compensation (a meaningful contributor to higher G&A in 2024) and one‑time equity‑related accounting swings (warrant fair‑value changes) that amplify reported compensation expense; R&D reductions after Phase 3 wind‑down have shifted total compensation mix toward retention and litigation‑period awards. Key performance drivers for pay will be clinical and regulatory readouts (IND filings, trial endpoints, REFOCUS topline), successful licensing/milestone captures (the Yale TSC license), cash‑runway metrics and fundraising outcomes (notably the Jan 2024 warrant exercises that raised material proceeds). Given the company’s small headcount and recent 33% staff cut, expect targeted retention grants for key clinical hires and executives to preserve institutional knowledge during the pivot.

Insider Trading Considerations

Insiders at Cassava are likely to hold concentrated equity positions and therefore commonly use option/warrant exercises and equity sales for tax or diversification; 2024–2025 filings already show large warrant activity and valuation swings that affect insider economics. Because the company’s material events are clinical readouts, IND submissions and licensing milestones, trading windows and blackout periods around data locks, top‑line announcements and regulator communications are especially important — material nonpublic information (MNPI) around trial results creates heightened market sensitivity. Regulatory and governance factors (the $40M SEC settlement, ongoing DOJ cooperation, and a former collaborator’s indictment) increase compliance scrutiny and may lead to tighter internal trading controls, possible 10b5‑1 plan adoption or suspension, and reputational-driven disclosures that trigger insider filings; short‑swing profit rules (Section 16) and standard biotech blackout practices make timely Form 4 monitoring useful for traders. Researchers and traders should watch for clustered insider option exercises, Form 4 sales following fundraising events, any new retention equity grants, and sudden changes in 10b5‑1 plans or trading windows around TSC program milestones.